Hong Kong Stock Alert | MIRXES-B (02629) Surges Over 35% Intraday to Record High as Singapore Cancer Screening Company Gets Added to Stock Connect

Stock News

Sep 15

MIRXES-B (02629) surged over 35% during intraday trading, reaching a record high of HK$59.5, representing a gain of more than 150% from its IPO price of HK$23.3. As of press time, the stock was trading up 24.43% at HK$54.75 with turnover of HK$566 million.

On the news front, according to an August 22 announcement by Hang Seng Indexes Company, Mirxes has been included in the Hang Seng Composite Index. The related changes took effect on September 8, and the company has officially become a constituent of Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect program.

According to public information, Mirxes is a Singapore-headquartered microRNA (miRNA) technology company dedicated to making disease screening and diagnostic solutions accessible across key Asian markets. As of the latest practicable date, the group has one core product (GASTROClear™), two other commercialized products (LUNGClear™ and Fortitude™), and six candidate products in preclinical stages.

The group's core product, GASTROClear™, is a blood-based miRNA test panel composed of 12 miRNA biomarkers for gastric cancer screening. The product was successfully commercialized in Singapore after obtaining a Class C in vitro diagnostic (IVD) certificate from Singapore's Health Sciences Authority (HSA) in May 2019.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1139458113"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139458113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139458113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 14:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139458113","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | MIRXES-B (02629) Surges Over 35% Intraday to Record High as Singapore Cancer Screening Company Gets Added to Stock Connect","media":"Stock News","content":"<p>MIRXES-B (02629) surged over 35% during intraday trading, reaching a record high of HK$59.5, representing a gain of more than 150% from its IPO price of HK$23.3. As of press time, the stock was trading up 24.43% at HK$54.75 with turnover of HK$566 million.</p>\n<p>On the news front, according to an August 22 announcement by Hang Seng Indexes Company, Mirxes has been included in the Hang Seng Composite Index. The related changes took effect on September 8, and the company has officially become a constituent of Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect program.</p>\n<p>According to public information, Mirxes is a Singapore-headquartered microRNA (miRNA) technology company dedicated to making disease screening and diagnostic solutions accessible across key Asian markets. As of the latest practicable date, the group has one core product (GASTROClear™), two other commercialized products (LUNGClear™ and Fortitude™), and six candidate products in preclinical stages.</p>\n<p>The group's core product, GASTROClear™, is a blood-based miRNA test panel composed of 12 miRNA biomarkers for gastric cancer screening. The product was successfully commercialized in Singapore after obtaining a Class C in vitro diagnostic (IVD) certificate from Singapore's Health Sciences Authority (HSA) in May 2019.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | MIRXES-B (02629) Surges Over 35% Intraday to Record High as Singapore Cancer Screening Company Gets Added to Stock Connect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | MIRXES-B (02629) Surges Over 35% Intraday to Record High as Singapore Cancer Screening Company Gets Added to Stock Connect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-15 14:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MIRXES-B (02629) surged over 35% during intraday trading, reaching a record high of HK$59.5, representing a gain of more than 150% from its IPO price of HK$23.3. As of press time, the stock was trading up 24.43% at HK$54.75 with turnover of HK$566 million.</p>\n<p>On the news front, according to an August 22 announcement by Hang Seng Indexes Company, Mirxes has been included in the Hang Seng Composite Index. The related changes took effect on September 8, and the company has officially become a constituent of Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect program.</p>\n<p>According to public information, Mirxes is a Singapore-headquartered microRNA (miRNA) technology company dedicated to making disease screening and diagnostic solutions accessible across key Asian markets. As of the latest practicable date, the group has one core product (GASTROClear™), two other commercialized products (LUNGClear™ and Fortitude™), and six candidate products in preclinical stages.</p>\n<p>The group's core product, GASTROClear™, is a blood-based miRNA test panel composed of 12 miRNA biomarkers for gastric cancer screening. The product was successfully commercialized in Singapore after obtaining a Class C in vitro diagnostic (IVD) certificate from Singapore's Health Sciences Authority (HSA) in May 2019.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCEI","symbol_name":"国企指数","start_time":0,"source_url":"","article_id":"1139458113","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139458113","pubTimestamp":1757918423,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"MIRXES-B (02629) surged over 35% during intraday trading, reaching a record high of HK$59.5, representing a gain of more than 150% from its IPO price of HK$23.3. As of press time, the stock was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HSCEI":"国企指数","YANG":"三倍做空富时中国ETF-Direxion","07226":"南方两倍做多恒科","BK4614":"Manus概念股","BK1161":"生物科技","02629":"MIRXES-B"},"translate_title":"港股快讯|新加坡癌症筛查公司加入沪股通MIRXES-B(02629)盘中大涨超35%创新高","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02629":1,"07226":1,"HSCEI":1,"YANG":1},"content_text":"MIRXES-B (02629) surged over 35% during intraday trading, reaching a record high of HK$59.5, representing a gain of more than 150% from its IPO price of HK$23.3. As of press time, the stock was trading up 24.43% at HK$54.75 with turnover of HK$566 million.\nOn the news front, according to an August 22 announcement by Hang Seng Indexes Company, Mirxes has been included in the Hang Seng Composite Index. The related changes took effect on September 8, and the company has officially become a constituent of Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect program.\nAccording to public information, Mirxes is a Singapore-headquartered microRNA (miRNA) technology company dedicated to making disease screening and diagnostic solutions accessible across key Asian markets. As of the latest practicable date, the group has one core product (GASTROClear™), two other commercialized products (LUNGClear™ and Fortitude™), and six candidate products in preclinical stages.\nThe group's core product, GASTROClear™, is a blood-based miRNA test panel composed of 12 miRNA biomarkers for gastric cancer screening. The product was successfully commercialized in Singapore after obtaining a Class C in vitro diagnostic (IVD) certificate from Singapore's Health Sciences Authority (HSA) in May 2019.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}